Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3933-3938

  Bossart, Michaela ^a   Becker, Meike ^a   Hadji, Peyman ^b   Kieback, Dirk G ^c   Hasenburg, Annette ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Elblandkliniken ^*  (Germany)

Author keywords

Adverse events; Analgesics; Aromatase inhibitor; Compliance; Exemestane; TEAM trial

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; DRUG USE; FEMALE; FRACTURE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; NERVE COMPRESSION; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLEEP DISORDER; THROMBOSIS; TREATMENT DURATION; VAGINA BLEEDING; VAGINA DRYNESS;

ANALGESICS; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; FEMALE; FRACTURES, BONE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 84866983178     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Coombes RC, Kilburn LS, Snowdon CF Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E and Bliss JM: Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369: 559-570, 2007.
2. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY and Tobias JS; ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005.
3. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN and Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757, 2005.
4. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD and Coates AS: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361: 766-776, 2009.
5. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
6. Aebi S, Davidson T, Gruber G and Castiglione M: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v9-14, 2009.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer V.2.2011. accessed at http://www.nccn.org/ professionals/physician-gls/pdf/breast.pdf on July 25, 2012.
8. Partridge AH, LaFountain A, Mayer E Taylor BS, Winer E and Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26: 556-562, 2008.
9. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM and Jones SE: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 377: 321-331, 2011.
10. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1): 13-47, 2000.
11. MedDRA Introductory Guide Version 12.1, 2009. Sep, MSSO-DI-6003-12.1.0.
12. Lash TL, Fox MP, Westrup JL, Fink AK and Silliman RA: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99: 215-220, 2006.
13. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F and Silliman RA: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4): 549-555, 2008.
14. Fabian CJ and Kimler BF: Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 23: 1644-1655, 2005.
15. Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Serin D, Gulcelik MA and Deschamp V: The impact of educational materials on compliance and persistence with adjuvant aromatase inhibitors: 2-year follow-up and final results from the CARIATIDE Study. San Antonio Breast Cancer Symposium (SABCS), P5-16-02, 2011.
16. Lück HJ, Hadji P, Harbeck N, Jackisch C, Blettner M, Zaun S, Windemuth-Kieselbach C, Beck T, Köhler U, Schmitt D and Kreienberg R: 24-month follow-up results from PACT (Patient's Anastrozole Compliance to Therapy). San Antonio Breast Cancer Sympostium (SABCS), P5-17-05, 2011.
17. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H and Goss PE: Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13: 829-837, 2008.
18. Hadji P, Ziller M, Kieback DG Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F and Hasenburg A: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: Results of a German, 12-month, prospective, randomised sub-study. Ann Oncol 20: 203-207, 2009.
19. Hadji P, Ziller M, Kieback DG Menschik T, Kalder M, Kuck J and Hasenburg A: The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 18: 159-164, 2009.
20. Kieback DG, Harbeck N, Bauer W Weyer G, Menschik T and Hasenburg A: Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy. Gynecol Oncol 119: 500-505, 2010.
21. Love RR, Mazess RB, Barden HS Epstein S, Newcomb PA, Jordan VC, Carbone PP and DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856, 1992.
22. Hadji P: Aromatase inhibitor-associated bone loss in breast cancer. US Oncol Dis 1: 18-21, 2007.